Orris

Sinus bradycardia under evaluation

Reading File
Finding Sources
Searching PubMed

"sinus bradycardia" AND evaluation

Searching the Web

sinus bradycardia evaluation diagnosis management guidelines 2024 2025

Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Loading Image
Loading Image
I now have comprehensive information from multiple authoritative textbooks plus the diagnostic algorithm and ECG images. Here is the full, structured response:

Sinus Bradycardia: Evaluation

Definition & ECG Recognition

Sinus bradycardia is a cardiac rhythm originating from the sinoatrial (SA) node at a rate below 60 bpm. Braunwald's Heart Disease uses a threshold of <50 bpm in adults for diagnostic purposes; Goldman-Cecil and clinical practice generally use <60 bpm, with rates of 45-50 bpm at rest considered physiologically normal.
ECG criteria:
  • Normal P wave morphology (upright in leads I, II, aVF)
  • Fixed P-P interval = R-R interval
  • P wave precedes every QRS complex
  • PR interval >120 ms (constant)
  • Sinus arrhythmia may coexist
ECG example - progressive sinus bradycardia due to heightened vagal tone during sleep (Goldman-Cecil Medicine):
Sinus bradycardia ECG strip

Physiologic vs. Pathologic

ContextInterpretation
Well-conditioned athlete, restingPhysiologic (high vagal tone)
Young adults during sleepPhysiologic
Rate <40 bpmJunctional escape rhythm may emerge
Symptomatic (syncope, presyncope, fatigue, HF worsening)Pathologic - requires workup

Causes

Medical Conditions (Harrison's 22E, 2025)

  • Hypothyroidism
  • Sleep apnea
  • Hypoxia
  • Hypothermia
  • Increased intracranial pressure
  • Lyme disease
  • Myocarditis
  • COVID-19
  • Vagal reflex (cough, pain, hemoperitoneum, inferior wall MI)
  • Carotid sinus hypersensitivity / vasovagal syncope
  • Intrinsic sinus node disease (sick sinus syndrome - age-related fibrosis)
  • Post-cardiac surgery / heart transplantation
  • Spinal cord injury (autonomic dysreflexia)

Medications (Goldman-Cecil Medicine / Harrison's 22E)

Cardiac drugs:
  • Beta-blockers (including ophthalmic beta-blocker eye drops)
  • Non-dihydropyridine calcium channel blockers (diltiazem, verapamil)
  • Digoxin, ivabradine
Antiarrhythmics:
  • Amiodarone, dronedarone, sotalol, flecainide, propafenone
Psychoactive / other:
  • SSRIs, tricyclic antidepressants, lithium
  • Opioid analgesics
  • Phenothiazines (antiemetics / antipsychotics)
  • Phenytoin
  • Cholinesterase inhibitors (donepezil)
  • Cannabis
  • Clonidine, methyldopa, propofol, remdesivir

Evaluation

History & Physical (most important first step)

  • Symptom correlation: fatigue, dizziness, near-syncope/syncope, exertional intolerance, worsening heart failure
  • Medication review (above list)
  • Contextual factors: athletic training, sleep state, acute illness

Initial Testing

  • 12-lead ECG - confirm sinus bradycardia, look for AV block, ischemic changes
  • Basic labs: TSH (hypothyroidism), electrolytes (hyperkalemia), Lyme serology if appropriate, troponin if ischemia suspected, toxicology if drug ingestion suspected

ACC/AHA/HRS Evaluation Algorithm (FIGURE 251-3, Harrison's 22E)

Diagnostic algorithm for sinus node dysfunction - ACC/AHA/HRS 2018 guideline
Algorithm steps (2018 ACC/AHA/HRS Guideline):
  1. Identify reversible/physiologic cause?
    • Yes → Treat underlying cause (sleep apnea, hypothyroidism, drug discontinuation) - Class I
    • If treatment effective or unnecessary → Observe
  2. Suspicion for structural heart disease?
    • Yes → Transthoracic echocardiography (Class IIa)
    • If suspicion for infiltrative cardiomyopathy, endocarditis, or adult congenital heart disease (ACHD) → Advanced imaging (Class IIa) (cardiac CT or cardiac MRI)
  3. Symptomatic?
    • No → Observe
    • Yes → Proceed
  4. Exercise-related symptoms?
    • Yes → Exercise ECG testing (Class IIa)
    • Not diagnostic / No → Ambulatory ECG monitoring (Class I) (Holter, event monitor, implantable loop recorder)
    • If electrophysiology study performed for other reasons → EPS (Class IIb)
  5. → Proceed to sinus node dysfunction treatment algorithm

Sinus Node Dysfunction Spectrum

Sinus bradycardia is part of the broader sinus node dysfunction (SND) spectrum, which includes:
  • Sinus bradycardia
  • Sinoatrial exit block (1st, 2nd [Type I/II], 3rd degree)
  • Sinus arrest (pause >2-3 seconds)
  • Chronotropic incompetence (max HR <100 bpm on exercise)
  • Tachycardia-bradycardia (tachy-brady) syndrome - alternating bradyarrhythmia and tachyarrhythmia (typically AF); identified by prolonged sinus node recovery after AF termination
  • Sick sinus syndrome = SND + symptoms (fatigue, dizziness, syncope, HF worsening)

Acute Management

Per Rosen's Emergency Medicine and 2025 AHA ACLS Algorithm:
SituationTreatment
AsymptomaticNo treatment, identify cause
Symptomatic (hemodynamically stable)Treat reversible cause; atropine 1 mg IV q3-5 min (max 3 mg)
Symptomatic (refractory to atropine)Dopamine 5-20 mcg/kg/min IV or epinephrine 2-10 mcg/min IV
Severe/unstableTranscutaneous pacing
Post-cardiac transplantIsoproterenol 2-10 mcg/min (atropine is ineffective due to denervation)
Hypothermia with confirmed sinus bradycardia + pulseAtropine and pacing usually NOT recommended (myocardial irritability)
Spinal cord injuryTheophylline/aminophylline (adenosine blockade)

Long-Term Management / Pacemaker Indications

  • Asymptomatic sinus bradycardia - NOT an indication for permanent pacing; not associated with adverse outcomes
  • Sleep-related pauses from high vagal tone without other symptoms - pacemaker generally not indicated
  • Symptomatic SND where symptom-rhythm correlation is established - permanent pacemaker is indicated
  • Tachy-brady syndrome - treat the tachyarrhythmia first (antiarrhythmics or catheter ablation); if pharmacologic AV nodal agents cannot be avoided, permanent pacing may be required
  • Reversible causes first - eliminate offending medications, treat hypothyroidism, revascularize if ischemia is driving bradycardia
  • Temporary pharmacologic options (when pacemaker must be delayed due to active infection, etc.): methylxanthines (theophylline) or beta agonists (terbutaline)
Key principle: There is no established heart rate below which pacemaker implantation is automatically indicated. The decision is symptom-driven and requires demonstrated symptom-rhythm correlation. - Harrison's Principles of Internal Medicine, 22E (2025)
Sources:
  • Harrison's Principles of Internal Medicine, 22E (2025, McGraw Hill) - p. 1963-1965
  • Goldman-Cecil Medicine, International Edition - p. 562
  • Braunwald's Heart Disease, 2-Vol Set - Chapter 68
  • Rosen's Emergency Medicine, 9e - Chapter 65
  • 2018 ACC/AHA/HRS Guideline on Evaluation and Management of Patients with Bradycardia and Cardiac Conduction Delay (via Harrison's Fig. 251-3)
  • 2025 AHA Adult Bradycardia With a Pulse Algorithm
This is a shared conversation. Sign in to Orris to start your own chat.